Zidovudine (300mg) + Lamivudine (150mg) + Nevirapine (200mg) tablet belongs to nucleoside reverse transcriptase inhibitors (NRTIs). The tablet is film coated, white to off-white colored, edged bevelled, capsule shaped, biconvex tablet debossed with ‘I’ on one side and ‘47’ on other side of the tablet.
The dose of this combination is fixed and cannot be changed once it is prescribed.
The tablet is given alone as complete regimen or in combination with other antiretrovirals medicine for treatment.
Zidovudine: It is a yellowish powder and nucleoside analog reverse transcriptase inhibitor (NRTI) and inhibits the enzyme reverse transcriptase. HIV uses this enzyme to make DNA and increase the inspection.
Zidovudine decreases the replication of the virus.
Lamivudine: It is a synthetic nucleoside and a (-) enantiomer of a dideoxy analog of cytidine. It is white to off- white crystalline solid and it is phosphorylated intracellularly to its active 5-triphosphate metabolite. It blocks the reverse transcriptase that HIV needs to make DNA and decreases the replication of the virus.
Nevirapine: It is a benzodiazepine non-nucleoside reverse transcriptase inhibitor. It reduces the viral loads of HIV and increases the counts of CD4 which strengthens the immune system and reduces the risk of AIDS.
The trio combination is used to treat HIV 1 infection in adults and children who weigh under 35kgs.
It is taken orally once and can be taken with or without food.
It strengthens the immune system by reducing the amount of HIV in the blood and reduces the risk of AIDS.
It prevents the multiplication of virus in the body and stand as a barrier for new infections, and viruses.
Observe for side effects of the tablet and consult your doctor immediately for treatment to avoid worsening of the complications.
Do not discontinue the dose unless your doctor suggests you to stop the medicine.
Monitor immediately if the patients show up the symptoms of hepatitis or hypersensitivity reaction.